Ketamine & DBTKetamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

Sponsor:

Joshua Rosenblat

Code:

NCT07569198

Conditions

Borderline Personality Disorder (BPD)

Treatment-Resistant Major Depressive Disorder

Treatment-resistant Bipolar Depression

Major Depressive Disorder (MDD)

Bipolar Disorder (BD)

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Ketamine Hydrochloride

Midazolam Hydrochloride

Dialectical Behavioral Therapy (DBT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-29. This information was provided to ClinicalTrials.gov by Joshua Rosenblat on 2026-07-29.